Table 1.
Patients’ baseline characteristics.
| Characteristic | n = 30 |
|---|---|
| Age | Median (range) |
| years | 69 (36–82) |
| Sex | n (%) |
| Male | 19 (63%) |
| Female | 11 (37%) |
| ECOG PS | |
| 0 | 5 (17%) |
| 1 | 17 (57%) |
| 2 | 8 (27%) |
| HER2 status | |
| positive | 7 (23%) |
| negative | 23 (77%) |
| Previous treatment regimens | |
| 1 | 2 (6.7%) |
| 2 | 21 (70%) |
| 3 | 7 (23%) |
| Previous therapy | |
| Fluoropyrimidine | 28 (93%) |
| Platinum | 24 (80%) |
| Taxane | 26 (87%) |
| Irinotecan | 3 (10%) |
| Ramucirumab | 22 (73%) |
| Trastuzumab | 5 (17%) |
| MSI/ MMR status | |
| dMMR | 1 (3%) |
| PD-L1 CPS | |
| ≥1 | 17 (57%) |
| <1 | 12 (40%) |
| Unknown | 1 (3%) |
Age median and range, ECOG PS Eastern Cooperative Oncology Group performance status, HER2 human epidermal growth factor receptor 2, MSI microsatellite instability, MMR DNA mismatch repair, dMMR deficient MMR, CPS combined positive score.